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A MULTIDISCIPLINARY INITIATIVE TO REDUCE VANCOMYCIN-RESIS-
TANT ENTEROCOCCUS (VRE) INCIDENCE ON A PEDIATRIC HEMATOPOI-
ETIC STEM CELL TRANSPLANT UNIT
Gainer, L.1, Johnson, B.1, Nickley, J.1, Potter-Bynoe, G.2, Scanlon, P.2,
Lehmann, L.3 1Children’s Hospital Boston, Boston, MA; 2Children’s Hos-
pital Boston, Boston, MA; 3Dana-Farber Cancer Institute, Boston, MA
Hematopoetic stem cell transplant (HSCT) patients are at risk for
bacteremia caused by resistant organisms, such as vancomycin-resis-
tant enterococcus (VRE), due to repeated courses of antimicrobial
therapy and neutropenia. Early VRE bacteremia during HSCT has
been associatedwith highmorbidity andmortality. Thus, implemen-
tation and monitoring of recommended infection prevention mea-
sures is critical. Recommendations include: judicious use of
antibiotics, health care worker education, hand hygiene compliance,
Standard and Contact precautions adherence, and surveillance for
VRE, which in our unit includes active surveillance cultures (ASC).
In the spring of 2008, an increase in VRE incidence prompted the
formation of amultidisciplinary team comprised ofHSCT, Infection
Control, and Environmental Services (ESD) personnel. Microbiol-
ogy records for our 13-bed pediatric HSCTunit revealed that the in-
cidence of VRE had increased from 1.8/1000 patient days in 2007 to
3.8/1000 patient days during the first 6 months of 2008. Our inves-
tigation revealed gaps in our ASC protocol. Admission ASC was of-
ten overlooked, making it difficult to determine whether the VRE
was acquired on our unit. To improve case finding, we emphasized
collecting ASC on admission with Infection Control performing
random audits to assess compliance. Our hospital protocol for dis-
continuing Contact precautions for patients with VRE is based on
serial rescreening. However, our investigation revealed that the pro-
tocol may not be applicable in HSCT patients prior to engraftment.
Therefore, HSCT patients with VRE must now be at least 100 days
post transplant before evaluation to discontinue Contact precautions
can be initiated. To address the potential role of the environment in
VRE transmission, we reviewed existing daily and discharge proce-
dures and enhanced the cleaning procedures of all patient rooms
and common areas. In lieu of restricting the use of common areas
by families, education on the importance of hand hygiene when en-
tering and leaving their child’s room was emphasized. As an added
measure, our unit requires HSCT patients to remain in their rooms
for the first 7 days of their admission to the unit. The use of preemp-
tive Contact precautions pending ASC results has been implemented
as an additional prevention strategy. During the 3rd quarter of 2008,
VRE incidence decreased to 1.9/1000 patient days and improvement
in compliance with our ASC protocol was realized.425
LOW-DOSE AZACITIDINE (AZA) AS MAINTENENCE THERAPY AFTER
ALLOGENEIC HEMATOPOIETIC STEM TRANSPLANTATION (HSCT) IN
RELAPSED AML OR MDS: A NURSING PERSPECTIVE
Metoyer, L.J., Champlin, R., Gulbis, A., da Silva, L., de Lima, M.,
Giralt, S. University of Texas at MD Anderson Cancer Center, Houston,
TX
Supportive care for allogeneic HSCT in patients with AML or
MDShas improved significantly over timewhich has resulted in a de-
crease in the rate of non relapse mortality. However, the incidence of
relapse has not been greatly impacted. Disease status at the time of
transplant is the most valid predictor for relapse, and recurrence re-
mains a major cause of treatment failure in this patient population.
Modification of treatment preparative regimens has not proven to
be beneficial. Despite the investigation of multiple chemotherapy/
radiation therapy combinations, reduction in the risk of relapse with-
out an increase of non relapsemortality has not been achieved for pa-
tients transplanted with relapsed and or refractory disease.
Azacitidine (AZA) is approved by the FDA for the treatment of
MDS at doses that are unlikely to be tolerated post HSCT due to
mylesuppression. In patients with relapsed AML or MDS at the
time of transplant, maintenance therapy with low dose AZA after
HSCT may provide adjuvant support for the allogeneic graft versus
leukemia affect, potentially decreasing recurrence rates. There is
limited experience with administration of chemotherapy and/or
the use of AZA in this setting. A dose and schedule finding study
for the use of AZA as maintenance therapy is being performed atMDAndersonCancer Center. AZA is given for four cycles in a doses
ranging from 8–32 mg/m2 starting on day1 42 subcutaneously daily
for 5 days every 28 days for a total of 4 cycles. Conditioning regimen
included gemtuzumab ozogamicin 2 mg/m2, fludarabine 120 mg/m2,
and melphalan140 mg/m2. Graft versus host disease (GVHD)
prophylaxis was tacrolimus/mini-methotraxate, with rabbit anti-
thymocyte globulin (rATG) in unrelated donor HSCT. Criteria for
patients to receive AZA include complete remission on day1 30 after
transplant with donor chimerism, no grade III/IV GVHD, platelets
greater than 10,000 and ANC. 500/ mm3. In all, 88 cycles were de-
livered at 8 (n5 7), 16 (n5 5), 24 (n5 21) and 32mg/m2 (n5 9). AZA
possible associated toxicities include grade I/II or III thrombocytope-
nia, grade I nausea, grade II fatigue, grade III transaminase elevation,
conjunctival erythema, prurititus, confusion, retinal hemorrhage,
grade II creatinine elevation, oral ulcers, papilledema and pulmonary
hemorrhage, and infections. Nursing issues related to drug adminis-
tration and monitoring will be discussed in further detail.426
PROPHYLACTIC CIPROFLOXACIN IN BK VIRUS POSITIVE ALLOGENEIC
STEM CELL TRANSPLANT RECIPIENTS AT KOSAIR CHILDREN’S HOSPITAL
Hente, M.L.1, Grant, J.O.1, Bowman, T.1, Wilkerson, R.1, Waldron, R.1,
Cheerva, A.C.2 1Kosair Children’’s Hosptial, Louisville, KY; 2University
of Louisville, Louisville, KY
Polyoma BK virus (BKV) is associated with hemorrhagic cystitis
(HC) in allogenenic stem cell transplants. This virus was first re-
ported in 1971, but testing for it has been available only for approx-
imately the past 5 years. It is very prevalent in human subjects (up to
80% of adults are infected), but only causes clinical issues in immu-
nocompromised patients possibly leading to hepatitis, retinitis,
pneumonitis and encephalopathy. Recent reports have suggested
that Ciprofloxacin (Cipro) can decrease urinary BKV reactivation af-
ter HSCT. Therefore, this institution began utilizing prophylactic
Cipro to attempt to reduce viral load and therefore, also the inci-
dence of HC. In this institution, Cipro was given prophylactically
to 4 BKV positive patients, of whom, 3 diagnoses were acute myeloid
leukemia and 1 diagnosis was acute lymphocytic leukemia. Two pa-
tients had BKV detected by PCR in their urine and no symptoms of
HC and 2 who were positive had moderate to severe clinical symp-
toms of HC. Standard preparative regimes were utilized with diverse
donor graft sources. All patients started with intravenous dosing of
Cipro, 1 with high dose due to severe HC and 3 with prophylaxis
dose. They were all switched to oral dosing when tolerated. All pa-
tients tolerated Cipro well and there were no side effects due to
this medication. Quantitative BKV PCR’s were done on urine at
least weekly and on serum if the patient became febrile. Urinalyses
were done frequently throughout the treatment period. Only 1 pa-
tient had positive serumPCR’s, whichwere noted prior to institution
of Cipro. The PCR continued to rise even with institution of Cipro
and never became negative. This patient succumbed to multiple in-
fections and GVHD (1145) after being on Cipro for 7 weeks. The
other patients (150, 1124 and1153) remain alive, 2 free of clinical
symptoms and off Cipro (given 17-50 and 130–50), and 1 remains
in the hospital on Cipro (150) and negative for clinical symptoms.
After initiation of Cipro, the BKV urinary viral loads decreased in
2 patients and increased in 2 patients. Two patients had HC before
starting Cipro (1 continued to increase viral load while the other de-
creased) and 2 did not have HC (1 continued to increase viral load
while the other did not). In conclusion, 50% of the patients in our
institution remained symptom free and a larger study should be
done to determine if Cipro is effective in decreasing BK urinary viral
loads and HC in stem cell transplant patients.427
A MULTIDISCIPLINARY CLINICAL PROCESS TO ADDRESS THE STEM CELL
TRANSPLANTATATION PATIENT WITH SPECIAL NEEDS
Tomczak, N., Davis, L., Neumann, J., Johnston, P., Sorenson, S. MD
Anderson Cancer Center, Houston, TX
Background: Undergoing a Stem Cell Transplantation (SCT)
can be a very complex process for patients, their caregivers, and
healthcare workers. When additional factors are included: a history
Poster Session-II 151of drug, alcohol, or tobacco use; caregiver concerns; psychiatric di-
agnosis; a patient history of no-compliance; the stress of this intense
treatment option becomes escalated for all involved. Such factors can
lead to complications during the transplant course including longer
hospital stays, increased stress to the patient, caregiver, and health-
care team, increase ethical issues, and subsequent poorer outcomes.
Early identification of such factors permits development of a plan of
care to facilitate optimal treatment courses. The SCTNurse plays an
important role in identifying and addressing these issues.
Intervention: A quality improvement process was developed to
help identify confounding factors and address them prior to treat-
ment. An algorithm, including a multidisciplinary care conference
(CC), provides a process flow for the healthcare team to follow.
When an issue is identified by any member of the outpatient health-
care team, a CC is requested. Participants of CC include Physician,
APN, SocialWorker, Clinical Ethicist, Advocacy, and Clinic and In-
patient Nurse; with optional members including Adolescent Young
Adult, Psychiatry and Chaplaincy. The goal of the CC is to discuss
concerns with the patient, answer patient/caregivers questions, and
promote communication across the care continuum.
Results: The result of this process is the development of an indi-
vidualized plan of care that may include postponement of transplant,
substance abuse programparticipation, care contracts, and/or formal
ethics consult. A case study will be presented that highlights how the
use of this process has lead to improved patient outcomes. Recom-
mendations The implementation of this or a similar process in any
SCT program will help facilitate the proactive identification of con-
cerns and promote patients safely going forward with treatment.428
BLOOD AND MARROW TRANSPLANT TELEPHONE TRIAGE: DEVELOP-
MENT OF A DOCUMENTATION TOOL TO ASSIST WITH CONCISE INFOR-
MATION GATHERING
Ensley, L.A., Powell, S., Anderson-Reitz, L. Baylor Charles A Sammons
Cancer Center, Dallas, TX
Purpose/Background: Blood and marrow transplant patients
present complicated issues throughout the transplant process. Post
allograft patients can have complications long after the initial trans-
plant period. Out-patient transplant recipients often present acute
issues that may require admission to an in-patient setting. Registered
nurses are presented with the challenge of assessment and triage of
these complicated patients by telephone communication. The need
for a concise communication and documentation tool was identified
to assist with both information gathering and formulating amedically
directed plan.
Intervention: This center has a designated telephone line for pa-
tient ‘‘sick calls’’. Patients or caregivers are directed to utilize this line
for any medical issues. We have developed a tool specific to blood
and marrow transplant issues and complications. The tool helps
the registered nurse concisely collect and document information
provided by the patient or caregiver. This tool is then utilized to
communicate these issues to the medical staff for a medical plan
that is documented on the tool. The tool is currently being utilized
within a pilot period for six months.
Evaluation: The tool will be evaluated at the end of six months.
Additions or deletions will then bemade to the tool. Continued eval-
uation of the tool will then be made on a yearly basis.
Discussion: Utilization of a regimented documentation tool will
assist with prompting the nurse in phone assessment and triage and
will allow for more concise reporting to the medical staff and ulti-
mately better plans of care.429
ASSOCIATION OF HEMATOPOIETIC STEM CELL PRODUCT CULTURE AND
CLINICAL INFECTION IN PATIENTS RECEIVING MYELOABLATIVE CHE-
MOTHERAPYWITH AUTOLOGOUS HEMATOPOIETIC STEM CELL REINFU-
SION
Cervone, K., Cartwright, F., Gardner, S. NYU Medical Center, New
York, NY
Purpose: The purpose of this descriptive retrospective QA pro-
ject is to examine the association between hematopoietic progenitorcell (HPC) product cultures at the time of reinfusion and the subse-
quent development of infection.
Methods:Using a descriptive, retrospective design, data were col-
lected from the records of 68 patients who received autologous pe-
ripheral blood HPC reinfusions after undergoing myeloablative
chemotherapy at a single institution. Consistent with the oncology
service QA program, all of the products were tested for microbial
contamination at the time of stem cell processing. At the time of re-
infusion, a sample from each thawed product was sent to the micro-
biology lab. Following theHPC reinfusion, blood cultures were sent
on patients at the time of their first fever and at least once daily until
they were afebrile and cultures were negative. Blood cultures were
sent from each lumen of the central venous catheter. Peripheral
blood cultures were not routinely drawn.
Results: Between March 2002 and September 2008, 68 patients
received 148 HPC reinfusions. All of the reinfused HPC products
were negative for bacterial contamination at the time of processing.
Nineteen of the reinfused HPC cultures, which were reinfused into
13 patients, were positive. Two of these patients developed positive
blood cultures. Patient #1 had HPC product culture positive for
Bacillus species and Staphhylococcus epidermis. Blood cultures
were positive only for S. epidermis on day 115. Patient #2 had
HPC product cultures positive for Streptococcus oralis. Blood
cultures were positive for Streptococcus mitis on day 14 and S.
epidermis on day 16.
Conclusions: There does not appear to be a strong correlation
between positive product cultures and the subsequent development
of positve blood cultures. Microbial testing at the time of HPC
reinfusion may not be necessary.430
PNEUMOCYSTIS CARINII PNEUMONIA (PCP) PROPHYLAXIS PROTOCOL
AFTER AUTOLOGOUS TRANSPLANTS: A RETROSPECTIVE REVIEW AT A
REGIONAL TRANSPLANT CENTER
Ramey, S.1, Bohnenblust, E.1, Smalling, D.1, Schisler, N.1,
Thompson, L.1, Schammel, C.1, Dillard, T.2, Fanning, S.2, Webb, S.2
1Furman University, Greenville, SC; 2Cancer Centers of The Carolinas,
Greenville, SC
Autologous hematopoeitic stem cell transplantion is an effective
treatment option for many hematological diseases. The morbidity
associated with this treatment, however, is often related to the in-
creased risk of infection following transplant due to an immunocom-
promised host. Prophylactic care designed to prevent infection varies
widely among institutions. In this retrospective analysis, we reviewed
the prophylactic protocol for Pneumocystis carinii pneumonia (PCP)
at Cancer Centers of the Carolinas (CCC), a regional transplant cen-
ter. All autologous hematopoietic stem cell transplants completed
for hematologic disorders between 2002 and 2007 (n 5 150) were
reviewed with regard to prophylactic Bactrim administration. The
standard operating procedure at CCC utilized Bactrim at a dose of
one double strength tab BID on Saturday and Sunday each week.
Protocol guidelines suggest prophylactic Bactrim initiation fourteen
days post transplant, continuing minimally through day 1200. At
day 200, the peripheral blood CD4 count was assessed. A CD4 count
of .200 cells/mliter prompted Bactrim discontinuation. Per proto-
col, values lower than this threshold necessitated CD4 count reas-
sessment at 100-day intervals until the threshold was achieved.
Results revealed 69% of patients were tested to threshold while
28% of patients were not tested to threshold. Of patients who
reached threshold, 76% had done so by d1260. The median 200
day post-transplant CD4 count assessed was 232 cells/mliter. The
number of days to reach threshold was not significantly different
when considering gender, race, or primary disease. However,
patients with multiple myeloma requiring tandem transplantion re-
sulted in significant delays in reaching threshold with non-tandem
patients reaching threshold in a median time of 200 days and tandem
patients reaching threshold in a median time of 282 days. These
results verify that, per protocol, d1200 is a valid point to initiate
assessment of CD4 count recovery following single autologous
transplantion. Patients having reached the threshold at this time
can discontinue Bactrim prophylaxis, and thus eliminate any
potential for Bactrim-associated side effects. Patients with CD4
counts below threshold at initial testing remain at risk for PCP
